TriSalus Life Sciences, Inc. (TLSI)
TLSI Stock Price Chart
Explore TriSalus Life Sciences, Inc. interactive price chart. Choose custom timeframes to analyze TLSI price movements and trends.
TLSI Company Profile
Discover essential business fundamentals and corporate details for TriSalus Life Sciences, Inc. (TLSI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Devices
IPO Date
8 Feb 2021
Employees
110.00
Website
https://trisaluslifesci.comCEO
Mary T. Szela B.S.N.,
Description
TriSalus Life Sciences, Inc., an immunotherapy company that develops and commercializes immunotherapies for the treatment of liver and pancreatic tumors. The company offers the TriNav Infusion System for hepatic arterial infusion of liver tumors; and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. It also develops SD-101, an investigational immunotherapeutic with pressure-enabled drug delivery technology for hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company is based in Westminster, Colorado.
TLSI Financial Timeline
Browse a chronological timeline of TriSalus Life Sciences, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 24 Mar 2026
Upcoming earnings on 13 Nov 2025
EPS estimate is -$0.14, while revenue estimate is $11.71M.
Earnings released on 12 Aug 2025
EPS came in at -$0.27 falling short of the estimated -$0.22 by -22.73%, while revenue for the quarter reached $11.21M , missing expectations by -3.76%.
Earnings released on 15 May 2025
EPS came in at -$0.33 falling short of the estimated -$0.20 by -65.00%, while revenue for the quarter reached $9.17M , beating expectations by +0.79%.
Earnings released on 27 Mar 2025
EPS came in at -$0.35 matching the estimated -$0.35, while revenue for the quarter reached $8.26M , beating expectations by +1.79%.
Earnings released on 14 Nov 2024
EPS came in at -$0.40 falling short of the estimated -$0.36 by -11.11%, while revenue for the quarter reached $7.35M , missing expectations by -0.39%.
Earnings released on 14 Aug 2024
EPS came in at -$0.21 surpassing the estimated -$0.49 by +57.14%, while revenue for the quarter reached $7.36M , beating expectations by +7.06%.
Earnings released on 15 May 2024
EPS came in at -$0.54 surpassing the estimated -$0.65 by +16.92%, while revenue for the quarter reached $6.46M , beating expectations by +4.69%.
Earnings released on 27 Feb 2024
EPS came in at -$1.34 , while revenue for the quarter reached $5.72M .
Earnings released on 14 Nov 2023
EPS came in at -$0.13 , while revenue for the quarter reached $5.19M .
Earnings released on 30 Jun 2023
EPS came in at -$0.53 , while revenue for the quarter reached $4.61M .
Earnings released on 31 Mar 2023
EPS came in at -$0.31 , while revenue for the quarter reached $2.98M .
Earnings released on 31 Dec 2022
EPS came in at -$0.76 , while revenue for the quarter reached $3.23M .
Earnings released on 10 Nov 2022
EPS came in at -$0.26 , while revenue for the quarter reached $3.92M .
Earnings released on 10 Aug 2022
EPS came in at $0.08 , while revenue for the quarter reached $2.88M .
Earnings released on 11 May 2022
EPS came in at -$0.25 , while revenue for the quarter reached $2.37M .
Earnings released on 2 Mar 2022
EPS came in at $0.09 , while revenue for the quarter reached $2.57M .
Earnings released on 13 Dec 2021
EPS came in at $0.06 .
Earnings released on 13 Dec 2021
EPS came in at -$0.00 .
Earnings released on 16 Aug 2021
EPS came in at $0.01 .
Earnings released on 28 Jun 2021
EPS came in at -$0.01 .
TLSI Stock Performance
Access detailed TLSI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.